MedTrace Logo

Quality Control of CE-Certified Phonak Hearing Aids - 2017_27

NCT03253003 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2017-09-25

No results posted yet for this study

Summary

A methodical evaluation of new CE-labelled Phonak Hearing Systems is intended to be conducted on hard of participants with a hearing loss to grant quality control prior to product launch. The aim of the investigation series is to ensure a stable overall performance of the new hearing systems, a good sound quality during phone calls as well as maximum benefit for the participant with the devices.

Conditions

  • Hearing Loss, Bilateral Sensorineural, Progressive

Interventions

DEVICE

Line extension of the Phonak Audéo B product family

The line extension of Phonak Audéo B product family will be fitted to the participants individual hearing loss.

Sponsors & Collaborators

  • Sonova AG

    lead INDUSTRY

Principal Investigators

  • Simone Ebbing, B. Sc. · Sonova AG

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-07
Primary Completion
2017-08-25
Completion
2017-08-25

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03253003 on ClinicalTrials.gov